alexa Vaccine Adjuvants; The Good, The Bad And The Ugly
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Nikolai Petrovsky
Keynote: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.019
Abstract
H ighly purified antigens suffer from poor immunogenicity. Current paradigms to address this problem focus onuse ofpotent innate immune activators as adjuvants, thereby mimicking natural infection. Unfortunately using this approach adjuvant immunogenicity and reactogenicity are largely inseparable. This talk will address the question of whether pro-inflammatory danger signals are really needed to make modern vaccines effective. Using examples of vaccines against influenza, West Nile virus, Japanese encephalitis virus and other important biodefense pathogens, data will be provided to show that bigger is not always better when it comes to vaccine adjuvants. Novel polysaccharide adjuvants such as delta inulin (Advax?) with more subtle immune effects surprisingly provide the best long-term immune memory responses and vaccine protection in the absence of generation of danger signals
Biography
Nikolai Petrovsky is the Director of endocrinology at Flinders Medical Centre with a conjoint position as Professor of Medicine at Flinders University. He is also Vice-president and secretary-general of the International Immunomics Society. He is active in diabetes, endocrinology and vaccine research. He is the Founder of Vaxine, a company funded by the US National Institutes of Health to develop novel vaccine technologies in 2009. He has developed vaccines against influenza, hepatitis B, sting allergy, malaria, Japanese encephalitis, rabies and HIV, has authored over 90 papers and chapters and is a regular invited speaker at international vaccine conferences
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords